Company intelligence / Profile preview

Mills Biopharmaceuticals

Oklahoma City, Oklahoma, United States

Ownership: Private
Development stage: Other

Overview

Mills Biopharmaceuticals was a medical technology and biotechnology company specializing in the development of radiopharmaceuticals for cancer treatment. The company's flagship product, ProstaSeed, is an Iodine-125 brachytherapy seed used in the treatment of localized prostate cancer. Based in Oklahoma City, Mills Biopharmaceuticals focused on improving the precision and manufacturing efficiency of radioactive seed implants. In July 2000, the company was acquired by U.S. Oncology for approximately $40 million to bolster its radiation oncology offerings. Following the acquisition, the ProstaSeed business was eventually sold to Theragenics Corporation in 2002.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Beyond the preview

Go deeper on Mills Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mills Biopharmaceuticals.

Explore the full profile